about
Hepatobiliary MR imaging with gadolinium-based contrast agentsMulti-OMICs and Genome Editing Perspectives on Liver Cancer Signaling NetworksCirculating MicroRNAs as Biomarkers in Biliary Tract CancersAn Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of CholangiocarcinomaTargeted Therapy in Biliary Tract CancersFunctional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancersResectable Cholangiocarcinoma: Reviewing the Role of Adjuvant StrategiesCancer review: CholangiocarcinomaThe significance of genetics for cholangiocarcinoma developmentCholangiocarcinomaIntrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapiesUnique genomic profile of fibrolamellar hepatocellular carcinoma.Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic ReviewStem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancerMicroRNA-26a promotes cholangiocarcinoma growth by activating β-cateninManagement of perihilar cholangiocarcinoma in the era of multimodal therapyClassification, diagnosis, and management of cholangiocarcinomaThe role of the hepatitis viruses in cholangiocarcinomaEpidemiology, risk factors, and pathogenesis of cholangiocarcinomaGene expression analysis for predicting gemcitabine resistance in human cholangiocarcinomaLoss of BAP1 Expression Occurs Frequently in Intrahepatic CholangiocarcinomaComprehensive review of BAP1 tumor predisposition syndrome with report of two new casesEpidemiology and risk factors: intrahepatic cholangiocarcinoma.Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: A multi-institutional analysis.Is Hepatic Resection for Large or Multifocal Intrahepatic Cholangiocarcinoma Justified? Results from a Multi-Institutional Collaboration.Recurrence after operative management of intrahepatic cholangiocarcinomaPhotodynamic therapy: Palliation and endoscopic technique in cholangiocarcinoma.Endoscopic management of hilar cholangiocarcinoma.Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells.A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures.Addition of Molecular Adsorbent Recirculating System (MARS(®)) Albumin Dialysis for the Preoperative Management of Jaundiced Patients with Hilar CholangiocarcinomaThe oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.Intrahepatic cholangiocarcinomaGenetic and molecular abnormalities in cholangiocarcinogenesis.Pancreatic recurrence of intrahepatic cholangiocarcinoma: Case report and review of the literature.What are the precursor and early lesions of peripheral intrahepatic cholangiocarcinoma?Reduced EBP50 expression levels are correlated with unfavorable clinicopathological features of extrahepatic bile duct carcinoma and promote the proliferation and migration of QBC939 cells.Therapeutic options for intrahepatic cholangiocarcinomaIn-hospital mortality after resection of biliary tract cancer in the United States.Etiological and clinicopathologic characteristics of intrahepatic cholangiocarcinoma in young patients.
P2860
Q24631773-D3DB3FD4-E9EC-4C42-91A7-3EE3A05CA68CQ26741086-44E950EE-EE13-4706-854A-07E2379D8A55Q26746000-B32D8566-11E3-47FC-9591-E7D1BA2DE5CAQ26784091-4D2F225F-DA9F-4CCF-A622-0764FA426236Q26798443-D4010645-87D4-4A98-811C-CD03FADE7BC6Q26830002-CF995622-BFB1-4F9C-85CC-A3FDFA6FC7EFQ26849394-BC234953-AAF5-4A5E-9FFC-90DA770856B9Q26865200-34C232FD-2344-408E-BAFA-40511903EB1DQ26865749-9259D023-8576-4B1D-A0FE-3923841CC624Q27001694-DAD4859C-BECA-4202-81FB-9852A51B7E0AQ27002547-96E60047-DCB9-4B1B-8AEA-2E9C195C6895Q27853116-0E17C8AD-4CB4-44DC-BB59-1211B094CB88Q28075370-6873BE4F-1485-43C1-BC99-5141F3F914F6Q28079205-0EE3E189-078E-4431-BEE6-766FB2FFC2AEQ28263940-B5A09BB2-CFC2-40F5-A967-EC4D32D3CEC9Q28273788-91ED1427-CFCB-41AB-89EB-8CE79FEBCDFEQ28275153-A31C6ED7-6F18-434E-B7E0-443581CFDFA4Q28288613-D2458EA2-503F-4FD2-A10A-9A8DD08CDA91Q28293076-1047DA30-78B1-427C-A39C-C10D9544A4D5Q28308112-2043A75A-78FA-4025-86BD-59A46F1C1B4CQ28384496-5B5D2F8E-F88F-412B-9497-EAF5F6D4A228Q28397229-1286C9B8-AB30-4010-93FF-E9E1C25A8E07Q30234461-612F9802-64AF-4C32-A4BF-B392E391B876Q30252624-4B5A16CA-94E4-4B39-AC79-BDBF246500F7Q30359582-BB0EB80D-4B02-4863-A6B4-B45E7DD34960Q30412886-EE45F7B6-E6F8-465E-9904-02D6D065C066Q30433853-15C630EE-C5F5-434B-B9DF-56B0B4EC699CQ31046234-67FD7B2E-2770-4D14-80B6-BD30F71ACDC1Q32174351-07A39E50-178B-473E-BF4C-5CE8205995ECQ33398969-AB755A55-D7F9-4979-94EB-EBFC934BC7BBQ33411158-23E0288F-10D4-4577-BB79-E464BB00F711Q33441341-74B45914-3E3E-47CE-859A-1415D78168E0Q33555135-145AF822-3AF0-421F-8597-FDB8EF4EF3A1Q33570262-0AD1FF63-B00A-4DF1-BB7A-5AF7E62C65DEQ33580993-6EE2E40A-4D35-4935-ACAA-06B75F1B46C4Q33594336-49110E1B-1A13-4AA9-BDA2-36805F25EE17Q33597837-123F5465-FD9B-4296-AB69-FD230004C3C9Q33621529-177FC28E-510F-4891-9367-3DD2603337FFQ33622816-D5934F62-24D9-4BA1-9F7C-04A467F0BC95Q33672901-203608E1-57C1-49CD-AF2D-4DE95529E793
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The epidemiology of cholangiocarcinoma.
@ast
The epidemiology of cholangiocarcinoma.
@en
type
label
The epidemiology of cholangiocarcinoma.
@ast
The epidemiology of cholangiocarcinoma.
@en
prefLabel
The epidemiology of cholangiocarcinoma.
@ast
The epidemiology of cholangiocarcinoma.
@en
P356
P1476
The epidemiology of cholangiocarcinoma.
@en
P2093
Hashem B El-Serag
Yasser Shaib
P304
P356
10.1055/S-2004-828889
P577
2004-05-01T00:00:00Z